Logo image of IS7.DE

INTICA SYSTEMS SE (IS7.DE) Stock Fundamental Analysis

FRA:IS7 - Deutsche Boerse Ag - DE0005874846 - Common Stock - Currency: EUR

1.89  +0.13 (+7.39%)

Fundamental Rating

2

Overall IS7 gets a fundamental rating of 2 out of 10. We evaluated IS7 against 49 industry peers in the Electronic Equipment, Instruments & Components industry. IS7 has a bad profitability rating. Also its financial health evaluation is rather negative. IS7 has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

IS7 had negative earnings in the past year.
IS7 had a positive operating cash flow in the past year.
In multiple years IS7 reported negative net income over the last 5 years.
IS7 had a positive operating cash flow in each of the past 5 years.
IS7.DE Yearly Net Income VS EBIT VS OCF VS FCFIS7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M

1.2 Ratios

Looking at the Return On Assets, with a value of -3.53%, IS7 is doing worse than 69.39% of the companies in the same industry.
IS7 has a Return On Equity of -11.86%. This is in the lower half of the industry: IS7 underperforms 65.31% of its industry peers.
Industry RankSector Rank
ROA -3.53%
ROE -11.86%
ROIC N/A
ROA(3y)1.39%
ROA(5y)1.2%
ROE(3y)3.97%
ROE(5y)3.5%
ROIC(3y)N/A
ROIC(5y)N/A
IS7.DE Yearly ROA, ROE, ROICIS7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5

1.3 Margins

In the last couple of years the Operating Margin of IS7 has declined.
The Gross Margin of IS7 (44.75%) is better than 67.35% of its industry peers.
IS7's Gross Margin has declined in the last couple of years.
IS7 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.75%
OM growth 3Y-64.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.82%
GM growth 5Y-3.61%
IS7.DE Yearly Profit, Operating, Gross MarginsIS7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 20 30 40

2

2. Health

2.1 Basic Checks

IS7 does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IS7 has about the same amount of shares outstanding.
Compared to 5 years ago, IS7 has about the same amount of shares outstanding.
Compared to 1 year ago, IS7 has a worse debt to assets ratio.
IS7.DE Yearly Shares OutstandingIS7.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
IS7.DE Yearly Total Debt VS Total AssetsIS7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

IS7 has an Altman-Z score of 1.28. This is a bad value and indicates that IS7 is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.28, IS7 is not doing good in the industry: 77.55% of the companies in the same industry are doing better.
The Debt to FCF ratio of IS7 is 10.62, which is on the high side as it means it would take IS7, 10.62 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 10.62, IS7 is in line with its industry, outperforming 48.98% of the companies in the same industry.
IS7 has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
IS7 has a Debt to Equity ratio (0.48) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 10.62
Altman-Z 1.28
ROIC/WACCN/A
WACC4.56%
IS7.DE Yearly LT Debt VS Equity VS FCFIS7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M 20M

2.3 Liquidity

IS7 has a Current Ratio of 0.97. This is a bad value and indicates that IS7 is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of IS7 (0.97) is worse than 89.80% of its industry peers.
IS7 has a Quick Ratio of 0.97. This is a bad value and indicates that IS7 is not financially healthy enough and could expect problems in meeting its short term obligations.
IS7 has a Quick ratio of 0.42. This is amonst the worse of the industry: IS7 underperforms 89.80% of its industry peers.
Industry RankSector Rank
Current Ratio 0.97
Quick Ratio 0.42
IS7.DE Yearly Current Assets VS Current LiabilitesIS7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

3

3. Growth

3.1 Past

The earnings per share for IS7 have decreased strongly by -780.87% in the last year.
IS7 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.22%.
IS7 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.63% yearly.
EPS 1Y (TTM)-780.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-141.67%
Revenue 1Y (TTM)-14.22%
Revenue growth 3Y6.92%
Revenue growth 5Y12.63%
Sales Q2Q%-27.94%

3.2 Future

Based on estimates for the next years, IS7 will show a very strong growth in Earnings Per Share. The EPS will grow by 28.28% on average per year.
Based on estimates for the next years, IS7 will show a decrease in Revenue. The Revenue will decrease by -3.63% on average per year.
EPS Next Y-159.26%
EPS Next 2Y-8.87%
EPS Next 3Y28.28%
EPS Next 5YN/A
Revenue Next Year-20.22%
Revenue Next 2Y-9.19%
Revenue Next 3Y-3.63%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
IS7.DE Yearly Revenue VS EstimatesIS7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
IS7.DE Yearly EPS VS EstimatesIS7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4 -0.6

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IS7. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IS7. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IS7.DE Price Earnings VS Forward Price EarningsIS7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IS7 is valued cheaply inside the industry as 81.63% of the companies are valued more expensively.
IS7's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IS7 is cheaper than 91.84% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.04
EV/EBITDA 5.47
IS7.DE Per share dataIS7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

IS7's earnings are expected to grow with 28.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.87%
EPS Next 3Y28.28%

0

5. Dividend

5.1 Amount

No dividends for IS7!.
Industry RankSector Rank
Dividend Yield N/A

INTICA SYSTEMS SE

FRA:IS7 (3/7/2025, 7:00:00 PM)

1.89

+0.13 (+7.39%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)11-19 2024-11-19
Earnings (Next)04-28 2025-04-28/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners60.42%
Ins Owner ChangeN/A
Market Cap8.11M
Analysts45.71
Price Target5.1 (169.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-204.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.11
P/FCF 3.04
P/OCF 1.24
P/B 0.44
P/tB 0.61
EV/EBITDA 5.47
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)0.62
FCFY32.89%
OCF(TTM)1.52
OCFY80.52%
SpS17.42
BVpS4.29
TBVpS3.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.53%
ROE -11.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.75%
FCFM 3.57%
ROA(3y)1.39%
ROA(5y)1.2%
ROE(3y)3.97%
ROE(5y)3.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4%
ROCE(5y)4.39%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-64.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.82%
GM growth 5Y-3.61%
F-Score4
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 10.62
Debt/EBITDA 1.43
Cap/Depr 57.66%
Cap/Sales 5.17%
Interest Coverage N/A
Cash Conversion 104.56%
Profit Quality N/A
Current Ratio 0.97
Quick Ratio 0.42
Altman-Z 1.28
F-Score4
WACC4.56%
ROIC/WACCN/A
Cap/Depr(3y)109.02%
Cap/Depr(5y)85.92%
Cap/Sales(3y)7.33%
Cap/Sales(5y)6.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-780.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-141.67%
EPS Next Y-159.26%
EPS Next 2Y-8.87%
EPS Next 3Y28.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.22%
Revenue growth 3Y6.92%
Revenue growth 5Y12.63%
Sales Q2Q%-27.94%
Revenue Next Year-20.22%
Revenue Next 2Y-9.19%
Revenue Next 3Y-3.63%
Revenue Next 5YN/A
EBIT growth 1Y-181.22%
EBIT growth 3Y-62.24%
EBIT growth 5YN/A
EBIT Next Year7300%
EBIT Next 3Y344.8%
EBIT Next 5YN/A
FCF growth 1Y21.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.86%
OCF growth 3Y-36.29%
OCF growth 5Y-6.03%